Skip to main content

ITP

2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Sunshine Biopharma
Sunshine BiopharmaQC - Varennes
1 program
1
TPOPhase 41 trial
Active Trials
NCT04089267Completed288Est. Aug 2019
Biocorp
BiocorpFrance - Issoire
1 program
1
autologous anti-BCMA chimeric antigen receptor T cellsPhase 21 trial
Active Trials
NCT05315778Unknown5Est. Jun 2023
Rigel Pharmaceuticals
Rigel PharmaceuticalsSOUTH SAN FRANCISCO, CA
1 program
FostamatinibN/ASmall Molecule1 trial
Active Trials
NCT04904276Terminated16Est. Nov 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Sunshine BiopharmaTPO
Biocorpautologous anti-BCMA chimeric antigen receptor T cells
Rigel PharmaceuticalsFostamatinib

Clinical Trials (3)

Total enrollment: 309 patients across 3 trials

NCT04089267Sunshine BiopharmaTPO

Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)

Start: Dec 2016Est. completion: Aug 2019288 patients
Phase 4Completed
NCT05315778Biocorpautologous anti-BCMA chimeric antigen receptor T cells

Anti-BCMA CAR T-Cell Therapy for R/R ITP

Start: Jan 2022Est. completion: Jun 20235 patients
Phase 2Unknown
NCT04904276Rigel PharmaceuticalsFostamatinib

Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy

Start: May 2021Est. completion: Nov 202216 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.